Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. (March 2018)

• Record Type: Journal Article
• Authors: Grossi, Francesco; Genova, Carlo; Rijavec, Erika; Barletta, Giulia; Biello, Federica; Dal Bello, Maria Giovanna; Meyer, Krista; Roder, Joanna; Roder, Heinrich; Grigorieva, Julia
• Is Part Of: Lung cancer. Volume 117(2018)
• Page Start: 64
• Page End: 69
• Publication Date: 2018-03
• Subjects: ALK anaplastic lymphoma kinase -- CPH Cox proportional hazard -- EGFR epidermal growth factor receptor -- ERCC1 excision repair cross-complementation group 1 protein -- HR hazard ratio -- MALDI ToF matrix-assisted laser desorption/ionization time-of-flight -- NSCLC non-small cell lung cancer -- OS overall survival -- PD-1 programmed cell death protein-1 -- PD-L1 programmed death-ligand 1 -- PFS progression-free survival -- PS performance status -- RRM1 ribonucleotide reductase subunit M1 -- TKI tyrosine kinase inhibitor; Non-small cell lung cancer -- VeriStrat -- Chemotherapy -- Biomarkers -- Prognosis -- First line therapy; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2017.12.007
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: VeriStrat was validated in many clinical studies as a prognostic and predictive test. The test's utility is now extended to standard first line chemotherapy. VeriStrat Poor patients have poor prognosis on standard first line chemotherapy. Those patients should consider clinical trials and other alternatives. Given its prognostic power, the test may be useful in stratification of clinical trials. Abstract: Objectives: VeriStrat ® is a blood-based test that utilizes matrix-assisted laser desorption/ionization time-of-flight (MALDI ToF) mass spectrometry to assign a binary classification of VeriStrat Good or VeriStrat Poor that is associated with treatment outcomes in cancer patients. A number of other studies have shown an association between VeriStrat status and clinical outcomes in second and subsequent lines of therapy. The prognostic properties of VeriStrat were demonstrated in the placebo arms of two randomized studies in non-small cell lung cancer (NSCLC): TOPICAL and BR.21; the predictive properties of the test were shown in a prospective randomized phase III study PROSE in the second line treatment of NSCLC with erlotinib versus chemotherapy. Motivated by these observations, we sought to extend the clinical utility of VeriStrat to standard first line chemotherapy and evaluated the performance of the test in a number of clinical studies of patients treated with platinum-based regimens. Materials and methods: We examine the performance of VeriStrat in three independent clinical trials where the test classification was acquired for prospectively collected baseline samples from 481 patients treated with platinum-based chemotherapy in first line. Results: Across these trials, 66–70% of patients were classified as VeriStrat Good; patients classified as VeriStrat Good had significantly longer progression-free survival and overall survival than VeriStrat Poor patients, with hazard ratios ranging from 0.36 to 0.72 and 0.26 to 0.51, respectively. These results demonstrated that VeriStrat is a strong prognostic test in NSCLC patients treated with platinum-based regimens in the first line. Conclusion: VeriStrat provides valuable clinical information that may be used to support patient-physician conversations regarding prognosis and treatment options, and to identify a subset of patients who might benefit from other treatment strategies, possibly in the framework of clinical trials.